REG - Oncimmune Hldgs PLC - Results of General Meeting and Total Voting Rights

Oncimmune HoldingsAnnouncement

08/11/2024 14:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241108:nRSH5834La&default-theme=true

RNS Number : 5834L  Oncimmune Holdings PLC  08 November 2024

 For immediate release

 

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Results of General Meeting and Total Voting Rights

 

Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company
providing research services to the pharmaceutical and biotechnology industry
to enable the delivery of precision medicine is pleased to announce that, at
the General Meeting held earlier today, all the Resolutions were duly passed.

 

The full text of the Resolutions can be found in the Notice of General
Meeting, which is contained in the Circular published and issued to
shareholders on 23 October 2024 and is available on the Company's website at:
www.oncimmune.com

 

The Company is pleased to confirm that as a result of obtaining shareholder
approval for the resolutions required to implement the Fundraising, , the
Company has raised total gross proceeds of approximately £2.3 million in
aggregate from the Fundraising.

 

5,500,000 Firm Placing Shares and 500,000 Firm Subscription Shares were
admitted to trading on AIM on 23 October 2024 on First Admission. Application
has been made to the London Stock Exchange for the admission of a total of
31,631,072 new Ordinary Shares to trading on AIM pursuant to the Second
Admission. Second Admission comprises (i) 6,500,000 Conditional Placing
Shares; (ii) 1,833,333 Conditional Subscription Shares (iii) 22,351,003
Conversion Shares and (iv) 946,736 Retail Offer Shares. These new Ordinary
Shares will rank pari passu with the Existing Ordinary Shares. Admission of
the Conditional Placing Shares, Conditional Subscription Shares, Conversion
Shares and Retail Offer Shares is expected to occur at 8:00 a.m. on 11
November 2024.

 

Total Voting Rights

 

Following Second Admission, the Company will have 111,773,219 Ordinary Shares
in issue and there are no shares held in treasury. This figure may be used by
shareholders as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a change to
their interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.

 

This announcement should be read in conjunction with the full text of the
Circular posted to Shareholders on 23 October 2024. Unless otherwise defined,
all capitalised terms used but not defined in this announcement shall have the
meaning given to them in the announcement of the Fundraising made by the
Company on 18 October 2024.

 

For further information:

 

Oncimmune Holdings plc

contact@oncimmune.com (mailto:contact@oncimmune.com)

 

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

Geoff Nash, Callum Davidson, Trisyia Jamaludin (Corporate Finance)

Nigel Birks (Life Science Specialist Sales)

Ondraya Swanson (ECM)

+44 (0) 20 7220 0500

 

Zeus (Joint Broker)

Dominic King, Dan Bate

+44 (0)20 3829 5000

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMEALFPEDKLFFA